The Multiple Myeloma Pipeline: Therapies to Watch

New investigational therapies in the pipeline that address multiple myelomainclude both small-molecule and immunotherapeutic approaches — and in some cases, a combination of the two.

Drugs that increase the visibility of tumors to the immune system, used in combination with additional medications that bolster the immune system, will be the future focus in the management of multiple myeloma, according to a study published in Trends in Cancer.1 These combination therapies are predicted to produce dramatic results in patients, bringing patients closer to achieving a functional cure — possibly extending median lifespan in patients with multiple myeloma by at least 10 years, said researchers.

Older therapies harness various mechanisms of action, with some working directly on plasma cells and others focused on fine-tuning the tumor microenvironment until it becomes an unwelcome place for tumors to reside.

Originally published on Cancer Therapy Advisor: